Scarica l'app Stockscreener
14.35
6.77%
0.91
Pre-mercato:
14.23
-0.12
-0.84%
Precedente Chiudi:
$13.44
Aprire:
$13.52
Volume 24 ore:
1.06M
Relative Volume:
0.54
Capitalizzazione di mercato:
$863.12M
Reddito:
$439.00K
Utile/perdita netta:
$-105.64M
Rapporto P/E:
-7.9722
EPS:
-1.8
Flusso di cassa netto:
$-60.70M
1 W Prestazione:
+4.74%
1M Prestazione:
+7.65%
6M Prestazione:
-40.06%
1 anno Prestazione:
-52.15%
Intervallo 1D:
$13.34
$14.46
Intervallo di 1 settimana:
$12.97
$14.46
Portata 52W:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.35 | 808.39M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring The 316.79% Potential Upside - DirectorsTalk Interviews
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating - marketscreener.com
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating - TipRanks
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Bitget
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Finviz
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st
Key facts: Janux Therapeutics Receives Strong Buy Ratings; Partners with BMS - TradingView
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating - TipRanks
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Guggenheim Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux Therapeutics, Inc. Q4 Loss Rises - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Janux Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q4 Revenue $0 - marketscreener.com
Bristol Myers deal and wider 2025 loss at Janux Therapeutics (JANX) - Stock Titan
Janux Therapeutics Q4 net loss widens on higher R&D expenses - TradingView
BRIEF-Janux Therapeutics Q4 Basic EPS USD -0.51 - TradingView
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
Technical Reactions to JANX Trends in Macro Strategies - Stock Traders Daily
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring A 376% Upside In Biotechnology - DirectorsTalk Interviews
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN
Why analysts remain bullish on Janux Therapeutics Inc. stockQuarterly Trade Report & Real-Time Chart Pattern Alerts - mfd.ru
Where is Janux Therapeutics (JANX) Headed According to Analysts? - Finviz
Janux Therapeutics (JANX) Expected to Announce Earnings on Thursday - MarketBeat
Janux therapeutics doses first participant in JANX011 phase 1 trial By Investing.com - Investing.com Australia
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - BioSpace
Janux therapeutics doses first participant in JANX011 phase 1 trial - Investing.com Nigeria
Janux Therapeutics, Inc. (JANX) Investor Outlook: A Potential 383.93% Upside in the Biotech Sector - DirectorsTalk Interviews
Janux Therapeutics Announces First Patient Dosed In Phase 1 Study Of Janx011 - TradingView
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year - AOL.com
Published on: 2026-02-15 18:41:23 - mfd.ru
Trading the Move, Not the Narrative: (JANX) Edition - Stock Traders Daily
Is Janux Therapeutics Inc. forming a bullish divergenceQuarterly Risk Review & Risk Controlled Stock Pick Alerts - mfd.ru
What is Janux Therapeutics Inc.’s valuation compared to sectorMarket Performance Recap & Low Drawdown Momentum Trade Ideas - mfd.ru
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring a Potential 379% Upside in Biotech Innovations - DirectorsTalk Interviews
Breakout Watch: What is Janux Therapeutics Incs debt to equity ratioDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags - Yahoo! Finance Canada
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowShould You Sell? - MarketBeat
(JANX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High? - Yahoo Finance UK
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007 - Insider Monkey
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bristol-Myers Squibb Expands Cancer Efforts With New AI And Drug Deals - Yahoo Finance UK
Why is Janux Therapeutics Inc. stock going downPortfolio Value Report & Weekly High Conviction Trade Ideas - mfd.ru
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):